Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders DOI Open Access
Riccardo Dalle Grave

IJEDO, Год журнала: 2024, Номер 6, С. 15 - 24

Опубликована: Ноя. 18, 2024

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications for managing obesity and related metabolic complications. However, their use presents specific challenges when is coexisting with eating disorders. In such cases, the appetite-suppressing effects of GLP-1RAs could potentially exacerbate behaviors like dietary restriction restraint, two behavioral patterns that help sustain disorder psychopathology, thus complicating treatment these Because concerns, it essential clinicians to screen disorders before prescribing in individuals overweight or obesity. Their currently contraindicated patients atypical anorexia nervosa, bulimia subthreshold as worsen restrictive common conditions. Although some emerging research suggests might reduce binge-eating episodes, there not yet enough evidence support specifically treating (BED) its associated psychopathology. According new recommendations from cognitive behavior therapy BED, may be cautiously considered clinical who do overvalue shape weight, have no history nervosa already made progress adopting regular reducing episodes.

Язык: Английский

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence DOI Creative Commons
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes

и другие.

Receptors, Год журнала: 2025, Номер 4(1), С. 2 - 2

Опубликована: Янв. 26, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) obesity. These agents mimic the action of endogenous incretin glucagon-like (GLP-1) by enhancing insulin secretion, inhibiting glucagon release, promoting weight loss through appetite suppression. GLP-1RAs have recently been suggested to neuroprotective effects, suggesting their potential as treatment neurodegenerative disorders, such Alzheimer’s disease (AD). AD T2DM share several common pathophysiological mechanisms, resistance, chronic inflammation, oxidative stress, mitochondrial dysfunction. shared mechanisms suggest that therapeutic targeting metabolic dysfunction may also be beneficial conditions. Preclinical studies on in models, both vitro vivo, demonstrated promising reductions amyloid-beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, enhanced neuronal survival. Despite encouraging results from preclinical challenges need addressed before can widely used treatment. Ongoing clinical trials investigating cognitive benefits patients, aiming establish role a option AD. This review aimed examine current literature GLP-1

Язык: Английский

Процитировано

1
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis DOI Creative Commons
Ping‐Tao Tseng,

Bing‐Yan Zeng,

Chih-Wei Hsu

и другие.

BMC Medicine, Год журнала: 2025, Номер 23(1)

Опубликована: Апрель 6, 2025

Abstract Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors represent a new generation of antihyperglycemic agents that operate through mechanisms distinct from conventional diabetes treatments. Beyond their metabolic effects, these medications have demonstrated neuroprotective properties in preclinical studies. While clinical trials explored therapeutic potential established neurodegenerative conditions, role disease prevention remains unclear. We conducted network meta-analysis (NMA) to comprehensively evaluate the prophylactic benefits across multiple diseases identify most promising preventive strategies. Methods systematically searched PubMed, Embase, ClinicalKey, Cochrane CENTRAL, ProQuest, ScienceDirect, Web Science, ClinicalTrials.gov October 24th, 2024, for randomized controlled (RCTs) GLP-1 or SGLT2 inhibitors. Our primary outcome was incidence seven major diseases: Parkinson’s disease, Alzheimer’s Lewy body dementia, sclerosis, amyotrophic lateral frontotemporal Huntington’s disease. Secondary outcomes included safety profiles assessed dropout rates. performed frequentist-based NMA evaluated risk bias with Risk Bias tool. The main result current study would be re-affirmed via sensitivity test Bayesian-based NMA. Results analysis encompassed 22 RCTs involving 138,282 participants (mean age 64.8 years, 36.4% female). Among all investigated medications, only dapagliflozin significant benefits, specifically preventing (odds ratio = 0.28, 95% confidence intervals 0.09 0.93) compared controls. Neither nor other showed effects any conditions. Drop-out rates were comparable Conclusions This comprehensive reveals novel specific effect against representing breakthrough neurology. specificity dapagliflozin’s protective might rely on its highly selective inhibition SGLT2. These findings provide important direction future research could inform strategies populations at Trial registration PROSPERO CRD42021252381.

Язык: Английский

Процитировано

1
Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer's Disease, Vascular Dementia, and Other Dementia Types Among Patients with Type 2 Diabetes DOI
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu

и другие.

Diabetes & Metabolism, Год журнала: 2025, Номер unknown, С. 101623 - 101623

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Cognitive disorders in diabetes DOI Creative Commons
Karim Gariani, Dongryeol Ryu, Manfredi Rizzo

и другие.

Frontiers in Clinical Diabetes and Healthcare, Год журнала: 2025, Номер 6

Опубликована: Фев. 24, 2025

Diabetes is increasingly recognized as a condition with far-reaching implications, including its impact on cognitive health (1). Early observations of the relationship between diabetes and impairment date back over century, initially based simple neuropsychological assessments comparing individuals without diabetes. Since then, large-scale epidemiological studies, advanced imaging technologies, neuropathological investigations have solidified this association, revealing complex interplay metabolic dysregulation decline (2,3). mis en forme : Anglais (Royaume-Uni) Code de champ modifié (Royaume-Uni)Today, it well-established that type 2 face 1.6-fold greater risk developing dementia compared to their non-diabetic peers. Estimates suggest affects 20% 70% people diabetes, depending study population examined (4). Beyond daily living, in associated higher cardiovascular events mortality Today, (5). The disorders shaped by multiple interacting factors, among which socioeconomic status plays crucial role. Education level, key determinant status, has been widely studied shown influence Individuals education tend lower risk, while those are more susceptible lifestyle-related diseases such hypertension, obesity, these conditions also decline, from backgrounds may experience severe rapid deterioration functions when living (6). This interconnected suggests disparities not only increase but contribute an accelerated through prevalence other diseases.Of note, recent COVID-19 pandemic demonstrated infected patients develop levels anxiety depression, well increased decline. Given at infections, can be hypothesized infection directly or indirectly worsen amplify diabetic (7). However, precise remains fully established.. For elderly individuals, particularly coexisting dementia, managing effectively becomes challenging. growing global projections pointing even steeper rise coming decades, diabetes-related emerging critical public challenge. These diminish quality life for millions worldwide impose substantial economic burdens healthcare systems both direct costs, treatments, indirect like lost productivity caregiving expenses.Cognitive now acknowledged significant complication It encompasses spectrum disorders, mild profoundly affect individuals' memory, attention, decision-making abilities. impairments complicate everyday activities, self-management creating feedback loop worsening glycemic control (8). Patients dysfunction often behavioral psychological challenges further impede ability follow medical advice, adhere treatment regimens, maintain consistent blood glucose monitoring. difficulties lead reduced adherence, less frequent monitoring, variability. cascading effects include recurrent episodes hypo-and hyperglycemia, exacerbate selfmanagement (9). vicious cycle compounded inherently demanding nature management. Decision-making about insulin dosing, meal planning, physical activity, medication adherence complex, requiring effort throughout day. impaired function, demands prove overwhelming, increasing complications diminishing (10).Research uncovered several factors contributing dual burden impairment. poor control, hypoglycemia, age, detrimental social isolation. Each exacerbates faced complicates Despite issues, awareness understanding professionals remain inadequate. Many report feeling unsupported misunderstood attempting address challenges, emphasizing urgent need enhanced specialized training providers (3).Adding complexity, develops insidiously, early subtle signs manifesting during middle age or, some cases, before 40 symptoms frequently overlooked attributed causes, delaying diagnosis intervention. highlights importance implementing proactive screening detection strategies, could significantly mitigate progression improve patient outcomes. despite recognition issue, integration into management guidelines relatively advancement. While represents positive step forward, application routine clinical practice inconsistent fragmented. To bridge gap, efforts needed standardize approaches, incorporate care, ensure teams equipped tools knowledge necessary effectively. will require improved commitment reshaping care models better serve burden.Despite awareness, gaps Current practices lack clear consensus most effective, how should performed, what thresholds prompt American Association (ADA) recommends annual aged 65 older, no specific guidance exists younger adults, evidence occur (11).While (11).Emerging therapies offer potential hope. Recently, FDA approved two anti-amyloid monoclonal antibodies Alzheimer's disease. treatments represent breakthroughare considered promising development, role populations unclear. Similarly, GLP-1 receptor agonists (GLP-1RAs), used management, neuroprotective preclinical studies neurodegenerative (12,13). preventing mitigating yet determined. In addition, use sodium-glucose cotransporters-2 inhibitors, another class novel anti-diabetic therapeutic agents, deficits, although exact mechanisms involved still elucicated (14). . Most existing expert opinion rather than robust data, underscoring comprehensive research. Longitudinal larger cohorts extended follow-up periods essential establish evidence-based practices. Technological advances, continuous monitoring (CGM), solutions improving CGMs enable real-time tracking levels, providing insights variability (15,16). accuracy limited extreme research optimize impairments.To impairment, collaborative, multidisciplinary approach just beneficial, -it essential. involve diverse team professionals, endocrinologists, specialists, primary physicians, educators, dietitians, therapists. By pooling expertise, create model optimizes resources, customizes meet unique needs each individual, ensures seamless pharmacological non-pharmacological strategies.In addition provided teams, professional societies hold pivotal catalyzing systemic change. organizations spearhead broad-based educational initiatives aimed providers, focusing raising intersection disorders. Such development targeted, patient-centered materials simplify information, making accessible actionable families affected conditions. Moreover, fostering stronger collaboration various specialties disciplines addressing multifaceted posed burden. Increased investment initiatives, terms funding strategic enhance manage overlapping impacts Through concerted efforts, system move toward holistic approach, ultimately outcomes affected.The link crisis. creates self-perpetuating undermines patients' Addressing issue requires deepen our underlying mechanisms, tailored strategies. New technologies already playing support older adults They efficient response fluctuations patient's needs, provide caregivers remote capabilities faster intervention crises, assist adjusting updating long-term plans patterns observed data collected. Furthermore, help evaluate selfmanagementAs continues obesity rates rise, diabetesrelated set dramatically. calls immediate action researchers, policymakers alike. investing advancing research, promoting we challenge worldwide.

Язык: Английский

Процитировано

0
Avances farmacológicos en la lucha contra la obesidad DOI

Pablo Caballero Portero

Panorama actual del medicamento, Год журнала: 2025, Номер 49(481), С. 154 - 182

Опубликована: Март 25, 2025

El presente artículo revisa en profundidad los principales aspectos etiopatogénicos, epidemiológicos y clínicos de la obesidad. También se detallan las opciones tratamiento, con especial atención al punto inflexión que ha supuesto incorporación agonistas del receptor GLP-1. Finalmente, destaca significativa función asistencial profesionales farmacéuticos para personas sufren obesidad, desde prevención mediante el fomento hábitos saludables hasta seguimiento farmacoterapéutico, fin alcanzar mantener un peso adecuado.

Процитировано

0
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders DOI
Riccardo De Giorgi, Ana Ghenciulescu,

Courtney Yotter

и другие.

Journal of Neurology Neurosurgery & Psychiatry, Год журнала: 2025, Номер unknown, С. jnnp - 335593

Опубликована: Апрель 10, 2025

Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed treatment of type 2 diabetes mellitus obesity, offer a novel, multilayered mechanism intervention neurodegeneration through intermediate, aetiology-agnostic pathways, likely involving metabolic, inflammatory several relevant neurobiological processes. In vitro animal studies have revealed promising signals neuroprotection, with preliminary supportive evidence emerging from recent pharmacoepidemiological investigations clinical trials. this article, we comprehensively review that investigate impact GLP-1RAs on various aetiologies impairment dementia syndromes. Focusing human studies, highlight how brain energy homeostasis, neurogenesis, synaptic functioning, neuroinflammation cellular stress responses, pathological protein aggregates, proteostasis, cerebrovascular system blood-brain barrier dynamics may underlie GLP-1RA putative neuroprotective effects. We then report appraise observational investigations, trials pooled analyses. Finally, discuss current challenges perspectives ahead research implementation care people their individual penetrance potential, need response biomarkers stage-based indications, possible non-specific effects health, profile terms adverse events unwanted effects, lack long-term data efficacy safety, issues surrounding cost availability treatment.

Язык: Английский

Процитировано

0
The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health DOI Creative Commons

Mohamad Al Qassab,

M.A. Mneimneh,

Ahmad Jradi

и другие.

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(4), С. 285 - 285

Опубликована: Апрель 17, 2025

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted beneficial effects on liver, kidney, cardiovascular health, mediated by both direct indirect mechanisms. In the GLP-1 RAs contribute to improvement of metabolic dysfunction-associated steatotic liver disease (MASLD) reducing hepatic fat accumulation, inflammation, oxidative stress. Additionally, they enhance insulin sensitivity lipid metabolism. Similarly, diabetic kidney (DKD), exhibit renoprotective properties mitigating stress, glomerular hypertension. Furthermore, promote natriuresis stabilize renal function. Moreover, present significant benefits, including improved myocardial function, reduced atherosclerosis progression, enhanced endothelial decreased major adverse events (MACEs). emerging evidence suggests may exert substantial neuropsychiatric reductions depressive symptoms, anxiety, substance use behaviors, lowering risk Alzheimer’s disease, Parkinson’s other dementias likely modulation neurotransmitter systems neuroinflammation. Genetic polymorphisms GLP1R gene also impact response, highlighting importance personalized medicine optimizing RA efficacy. This review synthesizes preclinical clinical supporting multifaceted across multiple organ systems, potential glycemic control. As advances, further exploration mechanisms action long-term outcomes, safety effectiveness diverse patient populations will be essential treating conditions.

Язык: Английский

Процитировано

0
GLP-1 Agonists for Weight Loss and Beyond DOI Open Access

Connor Quinter,

Hanh Motilall,

Kelley Maberry

и другие.

Transformative Medicine, Год журнала: 2024, Номер 3(4), С. 143 - 146

Опубликована: Дек. 19, 2024

Glucagon-like peptide-1 (GLP-1) agonists are medications that were originally approved for type 2 diabetes to help improve glycemic control in conjunction with exercise and dieting. One of the beneficial effects this medication class is weight loss, recently FDA has a select few indication loss. With these becoming increasingly more popular, it imperative both providers patients understand differences terms efficacy potential adverse events make best decision about initiating therapy. This article summarizes indications all GLP-1 includes supporting trial data showcasing their as loss treatments. Outside diabetes, there also may be other benefits seen agonist usage specific populations such cardiovascular disease, neurodegenerative diseases, non-alcoholic fatty liver steatohepatitis.

Язык: Английский

Процитировано

1
Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders DOI Open Access
Riccardo Dalle Grave

IJEDO, Год журнала: 2024, Номер 6, С. 15 - 24

Опубликована: Ноя. 18, 2024

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications for managing obesity and related metabolic complications. However, their use presents specific challenges when is coexisting with eating disorders. In such cases, the appetite-suppressing effects of GLP-1RAs could potentially exacerbate behaviors like dietary restriction restraint, two behavioral patterns that help sustain disorder psychopathology, thus complicating treatment these Because concerns, it essential clinicians to screen disorders before prescribing in individuals overweight or obesity. Their currently contraindicated patients atypical anorexia nervosa, bulimia subthreshold as worsen restrictive common conditions. Although some emerging research suggests might reduce binge-eating episodes, there not yet enough evidence support specifically treating (BED) its associated psychopathology. According new recommendations from cognitive behavior therapy BED, may be cautiously considered clinical who do overvalue shape weight, have no history nervosa already made progress adopting regular reducing episodes.

Язык: Английский

Процитировано

0